AdvanCell
PrivateLast Round
Series D
Jul 15, 2026
Total Funding Raised
$786.96M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AdvanCell is a clinical-stage radiopharmaceutical company that develops targeted alpha therapies for cancer treatment using a proprietary Lead-212 platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AdvanCell Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
AdvanCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 15, 2026 | ||||
| Grant | May 9, 2026 | ||||
| Grant | Apr 14, 2025 | ||||
| Series C | Feb 3, 2025 | ||||
| Series D | Jul 15, 2024 | ||||
Grant | Jul 5, 2023 |
Key People
Founding team and executive leadership
AdvanCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series D |
| SymBiosis Capital Management | Series D, Series C |
| SV Health Investors | Series D, Series C |
| Time BioVentures | Series D |
| Ally Bridge Group | Series D |
| Eventide Funds | Series D |
| Morningside Ventures | Series D, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 25, 2026
Presented novel TheraPb Phase 2 study design at ASCO GU Symposium 2026.
- Feb 25, 2026
Announced Phase 2 study design for ADVC001 at ASCO GU Symposium.
AdvanCell Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AdvanCell's valuation, stock price, and market status.